IJRR

International Journal of Research and Review

| Home | Current Issue | Archive | Instructions to Authors | Journals |

Case Report

Year: 2022 | Month: December | Volume: 9 | Issue: 12 | Pages: 187-191

DOI: https://doi.org/10.52403/ijrr.20221220

Successful Tumor Necrosis Factor (TNF) Inhibitor Therapy in Patients with Ankylosing Spondylitis: A Case Report

I Dewa Made Widya Sidartha1, Gede Kambayana1, Pande Kurniari1

1Rheumatology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Udayana/ RSUP Prof.IGNG Ngoerah, Denpasar, Bali, Indonesia

Corresponding Author: I Dewa Made Widya Sidartha

ABSTRACT

Introduction: Axial spondyloarthritis is a chronic inflammatory disease that mainly affects the axial skeleton. Anti-TNF can be a therapy of choice for ankylosing spondylitis.
Case Illustration: A 33-year-old male patient complained of chronic low back pain. The patient is diagnosed with ankylosing spondylitis based on New York Criteria 84. Initial therapy included NSAIDs for six months but showed no response. After we initiated the TNF inhibitor therapy, patients showed significant clinical improvement: BASDAI scores improved from 4.9 to 1.1, BASFI from 3.1 to 1.0, and ASDAS-CRP from 3.2 to 2.0.
Conclusions: Patient with ankylosing spondylitis who have no response to NSAIDs should be considered for TNF inhibitor administration. After six months of TNF inhibitor therapy, the patient responded well.

Keywords: Axial spondyloarthritis, ankylosing spondylitis, NSAIDs, Tumor Necrosis Factor.

[PDF Full Text]